| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
UKI-1 manufacturers
- UKI-1
-
- $347.00
-
2026-07-27
- CAS:220355-63-5
- Purity:
- Supply Ability: 10g
- UKI-1
-
- $347.00
-
2026-07-27
- CAS:220355-63-5
- Purity:
- Supply Ability: 10g
- UKI-1
-
- $347.00
-
2025-07-19
- CAS:220355-63-5
- Purity:
- Supply Ability: 10g
|
| Product Name: | UKI-1 | | Synonyms: | UKI-1;1-Piperazinecarboxylic acid, 4-[(2S)-3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-, ethyl ester;UKI-1C;UKI 1,UKI1;Upamostat Impurity 4;ethyl (S)-4-(3-(3-carbamimidoylphenyl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate | | CAS: | 220355-63-5 | | MF: | C32H47N5O5S | | MW: | 613.81 | | EINECS: | | | Product Categories: | | | Mol File: | 220355-63-5.mol |  |
| | UKI-1 Chemical Properties |
| Boiling point | 745.5±70.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 28 mg/mL (45.62 mM) | | form | Solid | | pka | 9.76±0.50(Predicted) | | color | White to off-white |
| | UKI-1 Usage And Synthesis |
| Uses | UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells[1][2]. | | in vivo | UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models[1]. | | References | [1] Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. DOI:10.1002/ijc.20192 [2] Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75. DOI:10.1006/jmbi.2000.3966 |
| | UKI-1 Preparation Products And Raw materials |
|